Pharvaris NV, a late-stage biopharmaceutical company, has announced the upcoming presentation of clinical trial data concerning deucrictibant, an oral bradykinin B2 receptor antagonist, for the treatment of hereditary angioedema $(HAE)$. The data will be showcased at the US Hereditary Angioedema Association's 2025 National Summit, scheduled from July 10-13 in Baltimore, Maryland. The presentations will cover various aspects of deucrictibant, including its long-term safety and efficacy, its durability of response for on-demand treatment, and a comparison with standard care. These findings will be presented on July 11, 2025, during a poster session. The posters will also be accessible on Pharvaris' website.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.